DOI: https://doi.org/10.22141/2224-0721.4.76.2016.77821

Clinical and Hormonal Characteristics of Patients with Giant Masses of Sellar-Chiasmatic Region

K.B. Alimova, Yu.M. Urmanova

Abstract


Objective: to study the clinical and hormonal characteristics of patients with giant masses of sellar-chiasmatic area. Material and methods. During the period from 2015 to 2016, we have examined 35 adult patients with pituitary macroadenomas, including 48.6 % of men. The average age of men was 37.12 years, women — 38.15 years. The disease duration ranged from 2 months to 25 years. Results. Distribution of patients according to topographic and anatomical classification of pituitary adenoma side growth showed that pituitary adenomas with total growth were (51.4 %) most frequent. Patients with giant pituitary adenomas most often had panhypopituitarism (44.4 %), as well as bitemporal hemianopsia (61.1 %) and secondary amenorrhea (33.3 %). Such disorders, as a secondary osteopenia, endocrine encephalopathy, delayed physical and sexual development, had been identified only in this group of patients. In addition, a significant decrease in the mean values of basal levels of tropic pituitary hormones (growth hormone (GH), luteinizing hormone (LH), follicle stimulating hormone (FSH), adrenocorticotropic hormone) was observed in patients with giant pituitary adenomas. Conclusions. Patients with giant pituitary adenomas have primarily a decrease in GH, FSH, LH levels. The most significant neuroendocrine and ophthalmic disorders occur in patients with giant pituitary adenomas.

Keywords


giant pituitary adenomas; clinical pattern; complications

References


Al-Shriam M. The 2004 World Health Organization classification of pituitary tumors. What is new? Acta neuropathol. 2006;111:1-7.

Komninos J, Vlassopoulou V, Protopapa D. Tumors metastatic to the pituitary gland: case report and literature review. J Clin Endocrinol Metab 2004; 89(2): 574-80.

Mortini P, Losa M, Barzaghi R. Results of transsphenoidal surgery in a large series of patients with pituitary adenoma. Neurosurgery. 2005;56:1222-1233.

Sara M, Claudio F, Marco L. Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother Oncol. 2011;99(1):23-8.

Tomlinson JW, Holden N, Hills RK, Wheatley K. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet. 2001; 357(9254):425-31.

Ezzat S, Asa SL, Couldwell WT. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101(3):613-19.

Colao A, Pivonello R, Di SC, Savastano S, Grasso LF, Lombardi G. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord. 2009;10(2):111-23.

Chanson P, Salenave S. Diagnosis and treatment of pituitary adenomas. Minerva Endocrinol. 2004;29(4):241-5.

Fatemi N, Dusick JR, de Paiva Neto MA, Kelly DF. The endonasal microscopic approach for pituitary adenomas and other parasellar tumors: a 10-year experience. Neurosurgery. 2008;63(4 Suppl 2):244-56.

Charalampaki P, Ayyad A, Kockro RA, Perneczky A. Surgical complications after endoscopic transsphenoidal pituitary surgery. J Clin Neurosci. 2009;16(6):786-9.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта